Recent

% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

sdhoolteach2000 123 posts  |  Last Activity: 14 hours ago Member since: Jun 20, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    STEPPING IT DOWN

    by sdhoolteach2000 20 hours ago
    sdhoolteach2000 sdhoolteach2000 14 hours ago Flag

    The stock price was stepped down this week by about 16%.

  • Reply to

    EBOLA is a DISTRACTION

    by flashfir 20 hours ago
    sdhoolteach2000 sdhoolteach2000 19 hours ago Flag

    Your right in saying Q flu & RSV is where it's at,however, the market views Ebola is being a price driver of the stock.

  • sdhoolteach2000 by sdhoolteach2000 20 hours ago Flag

    The MM are stepping down the price by continuing to short the stock. The shorts usually put 30% or more in a short position on a daily bases. I believe a few days ago they shorted upward of 60%. It looks like they'll continue doing so as long as there's money to be made and no developments are announced by the company.

  • Reply to

    New Game Plan: Accelerated Approval of Quad Flu???

    by bballgm Jul 31, 2015 1:22 AM
    sdhoolteach2000 sdhoolteach2000 22 hours ago Flag

    The excitement is building because the HAI numbers are off the chart. Additionally, the bird flu's negative affect on the number of eggs available to produce an egg based vaccine may also be a consideration. I do not know for sure if this is the case but the situation could get worse if the bird flu returns in the fall.

  • sdhoolteach2000 sdhoolteach2000 Jul 30, 2015 3:07 PM Flag

    i believe an FDA phase IV clinical is required to prove the vaccine is effective after the drug is on the market.

  • Reply to

    Citi's Response

    by mtkellner817 Jul 30, 2015 10:03 AM
    sdhoolteach2000 sdhoolteach2000 Jul 30, 2015 11:21 AM Flag

    bill, you are right on the publication aspect and if the results compare favorably to other Q flu vaccines we have a superior vaccine by virtue of the neuraminidase inhibitor
    I do not know whether or not you saw the release by the Univ of Penn on the immune system responding to a parasite,but this development could lead to a new avenue for the vlp tech or possibly the use of miscelles.
    I also note that the possible development of a universal vaccine is based on vlp or micelles binding to conserved part of the influenza virus, the stalk.
    We are in the right place,at the right time,and in the right field..

  • Reply to

    New Finding & Vaccines

    by sdhoolteach2000 Jul 29, 2015 11:21 AM
    sdhoolteach2000 sdhoolteach2000 Jul 29, 2015 4:45 PM Flag

    Research was done at the Univ of Pennsylvania.

  • Reply to

    New Finding & Vaccines

    by sdhoolteach2000 Jul 29, 2015 11:21 AM
    sdhoolteach2000 sdhoolteach2000 Jul 29, 2015 1:17 PM Flag

    Your right about resident immune cells residing in tissues that respond to viruses and other pathogens. Your also right I should have been more specific. The new finding is that memory T-cells respond to a parasite infection and it could lead to effective vaccines against parasitic diseases.It's the first time researchers have discovered an immune response against a parasite. It's an important finding.

  • sdhoolteach2000 by sdhoolteach2000 Jul 29, 2015 11:21 AM Flag

    A new finding shows that certain immune cells reside in tissues and that when a pathogen is encountered they invoke an immune response. This is the first time immune cells were found to reside in tissues and cause genes involved in an immune response. to increase in production.
    The finding could lead to the design of vaccines responsible for diseases that infect different tissues. It's another avenue for researchers at Novavax to explore.
    We are in the right place,at the right time,and in the right field.

  • sdhoolteach2000 sdhoolteach2000 Jul 29, 2015 10:18 AM Flag

    If there is a suitor, I like Pfizer. Their latest earnings report featured their vaccine division contributing to their higher earnings.

    Also, today's trading is showing that there's a seller.

  • Reply to

    How TB4 Regrows Hair

    by sdhoolteach2000 Jul 26, 2015 9:11 AM
    sdhoolteach2000 sdhoolteach2000 Jul 27, 2015 8:13 AM Flag

    sno, you're interpreting the statement in the wrong way. The authors are saying that before the the research was done the mechanism of action of TB4 was unknown, but now it is. The entire abstract explains what takes place to regrow hair in mice. IT IS THE MECHANISM OF ACTION!

  • Reply to

    How TB4 Regrows Hair

    by sdhoolteach2000 Jul 26, 2015 9:11 AM
    sdhoolteach2000 sdhoolteach2000 Jul 26, 2015 2:35 PM Flag

    Let's see how the research progresses before making any judgements as to the market value. If there's a way to grow hair such that it's thick and completely covers then a premium can be charged for the product. Now that the mechanism of action is known the call for improvements by major players is possible.

  • sdhoolteach2000 by sdhoolteach2000 Jul 26, 2015 9:11 AM Flag

    Researchers have discovered the mechanism of how TB4 regrows hair. With this discovery it should be easier to improve on the regrowth of regrowth.
    PLoS One. 2015 Jun 17;10(6):e0130040. doi: 10.1371/journal.pone.0130040. eCollection 2015.
    Thymosin Beta-4 Induces Mouse Hair Growth.
    Gao X1, Liang H1, Hou F1, Zhang Z1, Nuo M1, Guo X1, Liu D1.
    Author information
    Abstract

    Thymosin beta-4 (Tβ4) is known to induce hair growth and hair follicle (HF) development; however, its mechanism of action is unknown. We generated mice that overexpressed Tβ4 in the epidermis, as well as Tβ4 global knockout mice, to study the role of Tβ4 in HF development and explore the mechanism of Tβ4 on hair growth. To study Tβ4 function, we depilated control and experimental mice and made tissue sections stained with hematoxylin and eosin (H&E). To explore the effect of Tβ4 on hair growth and HF development, the mRNA and protein levels of Tβ4 and VEGF were detected by real-time PCR and western blotting in control and experimental mice. Protein expression levels and the phosphorylation of P38, ERK and AKT were also examined by western blotting. The results of depilation indicated that hair re-growth was faster in Tβ4-overexpressing mice, but slower in knockout mice. Histological examination revealed that Tβ4-overexpressing mice had a higher number of hair shafts and HFs clustered together to form groups, while the HFs of control mice and knockout mice were separate. Hair shafts in knockout mice were significantly reduced in number compared with control mice. Increased Tβ4 expression at the mRNA and protein levels was confirmed in Tβ4-overexpressing mice, which also had increased VEGF expression. On the other hand, knockout mice had reduced levels of VEGF expression. Mechanistically, Tβ4-overexpressing mice showed increased protein expression levels and phosphorylation of P38, ERK and AKT, whereas knockout mice had decreased levels of both expression and phosphorylation of these proteins.see pub med.

  • Reply to

    The CIDRAP Article

    by sdhoolteach2000 Jul 25, 2015 10:41 AM
    sdhoolteach2000 sdhoolteach2000 Jul 25, 2015 12:58 PM Flag

    BARDA

  • sdhoolteach2000 by sdhoolteach2000 Jul 25, 2015 10:41 AM Flag

    The recent CIDRAP article shows the direction new flu vaccines will take. The information will serve as a template to Novavax and investors alike. It's a must read.

  • Reply to

    and yet another patent awarded

    by thebasiles777 Jul 22, 2015 12:18 PM
    sdhoolteach2000 sdhoolteach2000 Jul 22, 2015 2:10 PM Flag

    The patent appears secondary to two US patents recently approved by the USPTO that are the primary focus of RGRX's technology and the patent allowance maybe useful for a future development.

  • Reply to

    Next Generation Influenza Vaccine: It's Ours?

    by sdhoolteach2000 Jul 22, 2015 11:25 AM
    sdhoolteach2000 sdhoolteach2000 Jul 22, 2015 12:31 PM Flag

    wily, the platform is "OURS" and NVAX is the key to producing the next generation VLP vaccines. It can't get much better than this.

  • Reply to

    Next Generation Influenza Vaccine: It's Ours?

    by sdhoolteach2000 Jul 22, 2015 11:25 AM
    sdhoolteach2000 sdhoolteach2000 Jul 22, 2015 11:38 AM Flag

    but it is, just ask the researchers at Novavax. And today's price rise is somewhat based upon the NIAID article.

  • Reply to

    Next Generation Influenza Vaccine: It's Ours?

    by sdhoolteach2000 Jul 22, 2015 11:25 AM
    sdhoolteach2000 sdhoolteach2000 Jul 22, 2015 11:33 AM Flag

    The news should give us a good indication of what to expect when the quadrivalent seasonal influenza results are announced.
    We are in the right place at the right time and in the right field.

  • Virus-like particle vaccine protects mice from many flu strains

    NIAID research could aid development of universal flu vaccine

    NIH/National Institute of Allergy and Infectious Diseases

    A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain. Now, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have devised a way to induce protective immunity in mice against a wide array of influenza viruses.

    Instead of trying to predict which influenza virus strains are likely to cause human disease and then make a vaccine to match those specific strains, Jeffery Taubenberger, M.D., Ph.D., and his colleagues created a vaccine cocktail incorporating four of the 16 different subtypes of an influenza virus protein called hemagglutinin (H). Two, H1 and H3, are typically found in human seasonal influenza viruses, and two, H5 and H7, are from avian influenza viruses that can also infect people. The experimental vaccine is made from non-infectious virus-like particles (VLPs) that stimulate an immune response, but that cannot replicate or cause disease. VLP vaccines already approved for use in people include those to protect against hepatitis B and human papillomavirus.

    In the new study, the NIAID scientists vaccinated mice with the VLP cocktail, then exposed them to lethal doses of several different influenza viruses. Importantly, in some of the experiments, mice were exposed to viruses from H subtypes not included in the cocktail vaccine. Vaccinated mice showed significant protection following challenge with influenza viruses expressing 1918 H1, 1957 H2, and avian H5, H6, H7, H10, and H11 H subtypes. There's more: see mBio

NVAX
12.06-0.05(-0.41%)Jul 31 4:00 PMEDT